YTHDF1 and YTHDF3 mediate recovery of HCC stemness and drug resistance through NOTCH1 activation [67] and HCC progression, migration, and EMT by targeting EGFR/STAT3 and WNT/β-catenin signaling axis (Figure 4) [68]. Here, EGFR is linked to hepatocellular carcinoma.